Get the Stockscreener App
15.56
2.57%
0.39
Keros Therapeutics Inc stock is traded at $15.56, with a volume of 674.95K.
It is up +2.57% in the last 24 hours and up +13.33% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$15.17
Open:
$15.41
24h Volume:
674.95K
Relative Volume:
1.33
Market Cap:
$631.98M
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-3.0331
EPS:
-5.13
Net Cash Flow:
$-146.15M
1W Performance:
+7.46%
1M Performance:
+13.33%
6M Performance:
+41.20%
1Y Performance:
-65.22%
1-Day Range:
$15.15
$15.81
1-Week Range:
$14.04
$15.81
52-Week Range:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
15.56 | 589.74M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-21-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-17-25 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-24 | Reiterated | Oppenheimer | Outperform |
| Dec-13-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-12-24 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-12-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-12-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-05-24 | Initiated | Jefferies | Buy |
| Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-23-24 | Initiated | Guggenheim | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
Connor Clark & Lunn Investment Management Ltd. Acquires 98,957 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Tejara Capital Ltd Takes $410,000 Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics Gains FDA Orphan Drug Designation - TipRanks
Keros gains Orphan Drug designation for Duchenne muscular dystrophy asset - Seeking Alpha
Keros Therapeutics Receives FDA Orphan Drug Designation for KER-065 in Duchenne Muscular Dystrophy Treatment - Quiver Quantitative
Keros Announces U.S. FDA Orphan Drug Designation Granted to - GlobeNewswire
FDA Grants Special Status to New Duchenne Muscular Dystrophy Drug: Keros' KER-065 Gets Orphan Designation - Stock Titan
Keros Therapeutics Inc. Tests 50 Day MA After Sharp DeclinePortfolio Gains Report & Low Risk High Reward Trade Ideas - thegnnews.com
Keros Therapeutics Inc. Building a Base Near SupportJuly 2025 Technicals & Trade Opportunity Analysis - newsyoung.net
How to build a dashboard for Keros Therapeutics Inc. stockTrade Risk Assessment & Low Risk High Reward Ideas - Newser
Applying Elliott Wave Theory to Keros Therapeutics Inc.Dip Buying & High Accuracy Swing Entry Alerts - Newser
Applying sector rotation models to Keros Therapeutics Inc.Market Trend Review & High Conviction Buy Zone Alerts - Newser
Why Keros Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Volume & Growth Focused Stock Reports - Newser
Is Keros Therapeutics Inc. forming a breakout pattern2025 Risk Factors & Consistent Income Trade Recommendations - thegnnews.com
Is Keros Therapeutics Inc. showing signs of accumulation2025 Key Lessons & Low Risk High Win Rate Stock Picks - Newser
Using data tools to time your Keros Therapeutics Inc. exitMarket Growth Review & Low Risk High Reward Ideas - Newser
What makes Keros Therapeutics Inc. stock price move sharply2025 Key Lessons & Weekly High Return Stock Opportunities - thegnnews.com
Does Keros Therapeutics Inc. qualify in momentum factor screeningDay Trade & Community Consensus Stock Picks - Newser
Will Keros Therapeutics Inc. continue its uptrend2025 Stock Rankings & Safe Entry Trade Reports - Newser
Is this a good reentry point in Keros Therapeutics Inc.Quarterly Trade Report & Weekly Momentum Picks - Newser
Key metrics from Keros Therapeutics Inc.’s quarterly dataPortfolio Return Report & Technical Entry and Exit Tips - Newser
Signal strength of Keros Therapeutics Inc. stock in tech scannersEarnings Recap Report & Daily Profit Maximizing Tips - Newser
Applying chart zones and confluence areas to Keros Therapeutics Inc.Entry Point & Community Trade Idea Sharing Platform - Newser
Combining price and volume data for Keros Therapeutics Inc.July 2025 Analyst Calls & Safe Capital Growth Plans - Newser
Is Keros Therapeutics Inc. stock trending bullish2025 Winners & Losers & Target Return Focused Picks - thegnnews.com
Can Keros Therapeutics Inc. hit a new high this monthForecast Cut & Free Weekly Chart Analysis and Trade Guides - Newser
Exit strategy if you’re trapped in Keros Therapeutics Inc.2025 Trading Recap & Growth Focused Entry Reports - Newser
Statistical indicators supporting Keros Therapeutics Inc.’s strengthQuarterly Earnings Summary & Free Weekly Watchlist of Top Performers - Newser
Keros Therapeutics Inc. Breaks Below Key Support LevelJuly 2025 Levels & Safe Entry Point Alerts - sundaytimes.kr
Leerink Partnrs Has Negative Estimate for KROS Q3 Earnings - MarketBeat
Q3 EPS Estimate for Keros Therapeutics Lowered by Analyst - MarketBeat
Technical Bounce Expected in Keros Therapeutics Inc. Next Week2025 Year in Review & Community Consensus Picks - thegnnews.com
Keros Therapeutics Reports Strong Revenue Growth - TipRanks
XTX Topco Ltd Invests $490,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $20.00 by Analysts at HC Wainwright - MarketBeat
HC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00 - Defense World
William Blair Predicts Lower Earnings for Keros Therapeutics - Defense World
Leerink Partners Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Keros Therapeutics stock price target lowered to $20 at H.C. Wainwright - Investing.com Canada
Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics - TipRanks
Keros prioritizes KER-065, pulls plug on cibotercept - The Pharma Letter
Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks - TipRanks
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $15 - 富途牛牛
Keros Therapeutics to discontinue cibotercept, announces COO departure - TipRanks
Keros Therapeutics, Inc. (NASDAQ:KROS) Holdings Raised by Federated Hermes Inc. - MarketBeat
Keros Therapeutics: Strategic Shift and Organizational Changes Prompt Hold Rating - TipRanks
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Keros Therapeutics Inc Stock (KROS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
0.30 |
49,367 |
14,810 |
302,223 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):